Compare Eli Lilly And Co (LLY) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Under Armour Inc Class A — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: Eli Lilly And Co is far larger — about 502.4× Under Armour Inc Class A's market cap, and Eli Lilly And Co pays a 0.59% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Under Armour Inc Class A for 18 Days on average.
| LLY | UA | |
|---|---|---|
Market Cap | $1.04T | $2.07B |
Volume | 3,064,878 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $7.88 |
52-Week Low | $799.57 | $3.96 |
Typical Hold Time | 93 Days | 18 Days |
Enterprise Value | $1.09T | $3.05B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Under Armour (UA) trades at $4.78, up 1.7% with a bullish technical signal despite negative profitability metrics. The company reported mixed quarterly results with two beats and one miss, while revenue declined to $4.9B in 2026 with a net loss of $492M. Analyst consensus shows 40% buy ratings but sentiment remains cautious due to ongoing revenue challenges and negative cash flow trends.
The outlook remains challenging with declining revenue and persistent losses, though the stock's low P/S ratio of 0.41 offers valuation support. Key risks include weak North American demand and competitive pressures, while potential catalysts require successful execution of turnaround strategies to restore profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
